

---

## AstraZeneca accelerates drug discovery thanks to PELE technology.

[AstraZeneca](#) in collaboration with [Heptares Therapeutic](#), has made significant progress with the new target called PAR<sub>2</sub>, using the [PELE](#) simulation software, as reported in [Nature](#). PAR<sub>2</sub> has applications for the generation of new drugs in the inflammatory pain field.

Specifically, this target is considered a highly promising drug target for the treatment of osteoarthritic pain. Until now, the discovery of small molecule antagonists to PAR<sub>2</sub> has proven very challenging. Locating multiple allosteric sites within PAR<sub>2</sub> offers alternative approaches for structure based drug design. This discovery has a direct impact on the generation of novel and promising new chemical lead series.

PELE is a technology developed at the Barcelona Supercomputing Center (BSC). [Nostrum Biodiscovery \(NBD\)](#) owns exclusive rights for the exploitation of this platform. Due to its latest upgrades and its multiple industrial validations, [PELE](#) is becoming one of the strongest technologies to consolidate relevant predictions in drug discovery.

Nostrum Biodiscovery - Rethink and Accelerate – May 2017

Link web [www.nostrumbiodiscovery.com](http://www.nostrumbiodiscovery.com) - mail: [info@nostrumbiodiscovery.com](mailto:info@nostrumbiodiscovery.com)

Press Contact: [jvasco@nostrumbiodiscovery.com](mailto:jvasco@nostrumbiodiscovery.com)

Jazmin Vasco Lacasta - +34 645 993 657

Press Contact: [communication@bsc.es](mailto:communication@bsc.es)

Gemma Ribas Maspoch - +34 675 785 975